On June 30th, Skyhawk Therapeutics shared a press release with new twelve-month data from the ongoing Phase 1/2 trial of ...

In a recent study, scientists created a chemical that breaks down expanded huntingtin HTT clumps in HD cells and mouse models. This chemical finds HTT clumps and targets them to be broken down or ...

Huntington’s disease (HD) involves the loss of cells in the striatum, an area of the brain that plays important roles in movement, cognition, and behaviour. For decades, researchers have been ...

SKY-0515 is a daily oral drug designed to lower both huntingtin, the protein that drives HD, and PMS1, a DNA repair protein linked to somatic CAG repeat expansion. Researchers hope this dual-target ...

A recent collaboration between researchers at the University of Leiden and the Huntington Expertise Center Topaz Overduin in the Netherlands has focused on an important yet often overlooked part of ...

uniQure shared in a press release on June 17, 2026 that the Food and Drug Administration (FDA) has agreed the 3-year data from their Phase I/II study can serve as the basis for a Biologics License ...

When your body makes new DNA, or fixes damaged DNA, it is assisted by a special protein called LIG1. If laying down DNA is like arranging a pattern of tiles, then LIG1 is the assistant who checks over ...